Gangloff Scott A. 4
4 · Akero Therapeutics, Inc. · Filed May 1, 2024
Insider Transaction Report
Form 4
Gangloff Scott A.
Chief Technology Officer
Transactions
- Award
Stock Option (Right to Buy)
2024-04-29+225,000→ 225,000 totalExercise: $19.62Exp: 2034-04-28→ Common Stock (225,000 underlying)
Footnotes (1)
- [F1]Twenty-five (25) percent of the shares subject to this option shall vest and become exercisable on April 29, 2025, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.